Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 13/20 | 0.52 |
| ▸ | PPARA | Q07869 | 8/20 | 0.52 |
| ▸ | PPARD | Q03181 | 3/20 | 0.52 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4337270 | 0.99 | PPARG (0.50) | PPARGPPARAPPARDMRGPRX4BCL2L1 | |
| SCHEMBL4336529 | 0.87 | MRGPRX4 (0.46) | PPARGPPARAPPARDMRGPRX4HRH3 | |
| SCHEMBL4336229 | 0.86 | MRGPRX4 (0.46) | PPARGPPARAPPARDMRGPRX4HRH3 | |
| SCHEMBL4332364 | 0.86 | PPARG (0.53) | PPARGPPARAPPARD | |
| SCHEMBL4335092 | 0.84 | PPARG (0.54) | PPARGPPARAPPARD | |
| SCHEMBL4340019 | 0.84 | PPARG (0.54) | PPARGPPARAPPARDPTGESALOX5 | |
| SCHEMBL4337259 | 0.84 | PPARG (0.52) | PPARGPPARAPPARDMRGPRX4HRH3 | |
| SCHEMBL4338050 | 0.82 | PPARG (0.50) | PPARGPPARAPPARDMRGPRX4 | |
| SCHEMBL4334780 | 0.81 | PPARA (0.57) | PPARGPPARAPPARDPTGESALOX5 | |
| SCHEMBL4337946 | 0.81 | PPARG (0.56) | PPARGPPARAPPARDPTGESALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1380562-A1 | CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | GPR119, IRS1, SLC5A1 | PPARG 379/4885PPARA 339/4885PPARD 753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.